Compare Southwest Airlines Co (LUV) vs Moderna, Inc. (MRNA) Price & Performance

Southwest Airlines (LUV) trades at $48.69, up 1.27% today, with a neutral technical signal. The stock shows mixed earnings results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with Q2 2026 results pending. Revenue grew to $28.06B in 2025, though net income margin declined to 1.57%. Analyst consensus is a Buy with a $52.47 price target, indicating potential upside. Recent news highlights Q2 earnings anticipation and sector-wide factors like fuel costs and travel demand.

The outlook for LUV is cautiously optimistic, driven by resilient travel demand and cost management efforts. Key opportunities include earnings growth potential and favorable analyst targets. Risks involve fuel price volatility, competitive pressures, and execution challenges. Investors should weigh strong institutional interest against macroeconomic headwinds affecting the airline industry.

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.